Pharmacotherapy and Pharmaceutical Care
The four-question framework
Pharmaceutical care means accepting responsibility for a patient's drug-related needs. Every therapy question maps to one of four failures: wrong indication, ineffective therapy, unsafe therapy, or nonadherence. Naming the category before reading the answer choices prevents most errors.
Concepts you must own
- Guideline-directed first-line therapy and the preferred agent in a patient with a specific comorbidity (heart failure, CKD, asthma, diabetes, depression, anticoagulation).
- Renal and hepatic dose adjustment, and which drugs accumulate or are directly nephrotoxic.
- Monitoring: the correct lab, the correct interval, and the target. INR 2–3 for most atrial fibrillation and VTE indications; potassium and creatinine after starting an ACE inhibitor, ARB, or MRA; A1c every 3 months until stable; TSH 6–8 weeks after a levothyroxine change.
- Duplication and interaction patterns: stacked RAAS blockade, serotonergic combinations, additive QT prolongation, CYP3A4 inhibitors and inducers, anticholinergic burden, and Beers criteria in older adults.
Traps
Questions plant an attractive but contraindicated option, such as a nonselective beta blocker in asthma, an MRA with potassium 5.4, metformin at an eGFR of 25, or two NSAIDs. Read whether the stem asks for the best initial step (often nonpharmacologic or a dose adjustment) versus the next step after treatment failure. Reject any monitoring parameter that does not match the drug in the stem.
Worked example
A 70-year-old with HFrEF (EF 30%), eGFR 38 mL/min, and potassium 5.2 on lisinopril and carvedilol. Spironolactone is guideline-supported therapy, but the potassium exceeds the threshold for safe initiation and renal function is borderline. The correct move is to hold the MRA, review potassium-raising contributors, and recheck labs rather than add blindly.